KR20240042400A - 결정질 형태 - Google Patents

결정질 형태 Download PDF

Info

Publication number
KR20240042400A
KR20240042400A KR1020247000169A KR20247000169A KR20240042400A KR 20240042400 A KR20240042400 A KR 20240042400A KR 1020247000169 A KR1020247000169 A KR 1020247000169A KR 20247000169 A KR20247000169 A KR 20247000169A KR 20240042400 A KR20240042400 A KR 20240042400A
Authority
KR
South Korea
Prior art keywords
piperidine
oxo
dimethyl
crystalline form
oxoindolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247000169A
Other languages
English (en)
Korean (ko)
Inventor
히데유키 아오야마
토요하루 누마타
마사키 수도
야스히로 이와타
Original Assignee
라퀄리아 파마 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 라퀄리아 파마 인코포레이티드 filed Critical 라퀄리아 파마 인코포레이티드
Publication of KR20240042400A publication Critical patent/KR20240042400A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
KR1020247000169A 2021-07-30 2022-08-01 결정질 형태 Pending KR20240042400A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163227692P 2021-07-30 2021-07-30
US63/227,692 2021-07-30
PCT/JP2022/029430 WO2023008585A1 (en) 2021-07-30 2022-08-01 Crystalline forms

Publications (1)

Publication Number Publication Date
KR20240042400A true KR20240042400A (ko) 2024-04-02

Family

ID=85087024

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247000169A Pending KR20240042400A (ko) 2021-07-30 2022-08-01 결정질 형태

Country Status (10)

Country Link
US (1) US12552776B2 (https=)
EP (1) EP4377309A4 (https=)
JP (1) JP7765130B2 (https=)
KR (1) KR20240042400A (https=)
CN (1) CN117616022A (https=)
BR (1) BR112023025271A2 (https=)
CA (1) CA3223173A1 (https=)
MX (1) MX2024000903A (https=)
TW (1) TW202321216A (https=)
WO (1) WO2023008585A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12605394B2 (en) 2024-07-25 2026-04-21 Visionary Assets, Llc Compositions containing cannabinoid nanoparticles

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2600510C (en) 2005-03-11 2010-11-02 Pfizer Inc. Crystal forms of an imidazole derivative
KR101575703B1 (ko) * 2009-02-27 2015-12-10 라퀄리아 파마 인코포레이티드 모틸린 수용체에 대해 작용제 활성을 가진 옥시인돌 유도체
WO2012157288A1 (en) 2011-05-18 2012-11-22 Raqualia Pharma Inc. Polymorph form of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2h-pyran-4-carboxylic acid
UY34094A (es) 2011-05-27 2013-01-03 Novartis Ag Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
CA2867043A1 (en) 2012-05-03 2013-11-07 Novartis Ag L-malate salt of 2,7-diaza-spiro[4.5]dec-7-yle derivatives and crystalline forms thereof as ghrelin receptor agonists
CA2944982C (en) 2014-05-20 2022-06-07 Raqualia Pharma Inc. Benzisoxazole derivative salt

Also Published As

Publication number Publication date
BR112023025271A2 (pt) 2024-02-27
EP4377309A1 (en) 2024-06-05
EP4377309A4 (en) 2025-06-25
JP7765130B2 (ja) 2025-11-06
JP2024526952A (ja) 2024-07-19
TW202321216A (zh) 2023-06-01
CN117616022A (zh) 2024-02-27
US20240351998A1 (en) 2024-10-24
US12552776B2 (en) 2026-02-17
CA3223173A1 (en) 2023-02-02
WO2023008585A1 (en) 2023-02-02
MX2024000903A (es) 2024-02-06

Similar Documents

Publication Publication Date Title
CA2836372C (en) Polymorph form of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2h-pyran-4-carboxylic acid
CN104837836B (zh) 多晶型物
HK1251553A1 (zh) 苯并异恶唑衍生物盐
JP7765130B2 (ja) 結晶形
HK40101847A (zh) 晶形
CA2910123A1 (en) Polymorph form of 2-amino-n-[2-(3a-(r)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro­pyrazolo[4,3-c]pyridin-5-yl)-1-(r)-benzyloxymethyl-2-oxo-ethyl]-isobutyramide l-tartrate
HK1231483B (en) Benzisoxazole derivative salt
HK1209122B (en) Polymorphs of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2h-pyran-4-carboxylic acid as 5-hydroxytryptamine-4 (5-ht4) receptor agonists for the treatment of gastrointestinal diseases
HK1195066B (en) Polymorph form of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2h-pyran-4-carboxylic acid
HK1216312B (en) Polymorph forms

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000